Milestone Scientific (MLSS) Analyst Target Points to +330% Upside Potential

Key Takeaways

• The central target discussed here is $1.25, the arithmetic mean of two verified analyst price targets currently in circulation — a low of $1.00 and a high of $1.50.
• With shares recently trading near $0.29, reaching $1.25 would require a gain of roughly 330%, a very large move for any listed company.
• The analyst target range is unusually wide ($1.00 to $1.50), and coverage is thin at just two firms, which adds uncertainty to any single figure.
• The strongest supporting factors are accelerating adoption of the CompuFlo platform, full-year 2026 revenue guidance of $9.8–$10.2 million, and early federal healthcare channel access.
• The biggest risks are a company that still generates losses, sequential revenue softness in the third quarter, recurring capital needs, and a sub-$30 million market cap.
• You can explore more about this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
• For a broader look at data-driven trading tools, explore Trending AI Robots.

Analyst Price Targets and Consensus View

Milestone Scientific Inc. (MLSS) is a biomedical technology company that develops computer-controlled injection and drug-delivery systems under the CompuFlo and CompuDent/STA brands. Unlike a diversified ETF, it is a single micro-cap stock, so its price target rests almost entirely on a small number of sell-side research desks.

Two current, individually attributable targets were reviewed. The low of $1.00 comes from Maxim Group, which reiterated its rating in May 2026. The high of $1.50 comes from Benchmark, which raised its target from $1.00 to $1.50 in August 2026. The arithmetic mean of these two figures is $1.25, a level consistent with the average shown by data aggregators such as MarketWatch and Yahoo Finance. The range of $1.00 to $1.50 is wide, and with only two firms covering the name, the average analyst price target should be read as directional rather than precise. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Both desks carry bullish ratings, but their reasoning diverges in scale. The more conservative $1.00 view emphasizes gradual commercial adoption and near-term cash constraints, while the $1.50 view assigns greater weight to faster CompuFlo penetration and a higher forward valuation multiple. No sell or hold rating currently appears in the dataset.

Current Market Position and Path Toward the Target

Shares recently traded near $0.29, toward the lower end of a 52-week range of roughly $0.22 to $0.58. A move to $1.25 would therefore require an upside of approximately 330%, which is a very large move. For context, the stock would need to more than quadruple, and would have to clear its 52-week high near $0.58 before any path toward $1.00 or beyond becomes relevant.

The company generated about $9.4 million in trailing revenue and posted a net loss of roughly $4.1 million over the same period. Trailing EPS (earnings per share) is negative, so the name lacks a conventional P/E (price-to-earnings) ratio to anchor valuation. The path toward $1.25 would almost certainly depend on sustained double-digit revenue growth, an inflection toward profitability, and investors assigning a meaningfully higher multiple to a business currently valued at about $26–27 million.

What Could Support a Move Toward the Target

• CompuFlo momentum: The medical segment grew sharply in the second quarter of 2026, driven by CompuFlo adoption and a study reporting a 91% reduction in procedure complications.
• Reaffirmed guidance: Management has repeatedly reiterated full-year 2026 revenue guidance of $9.8 million to $10.2 million, implying double-digit growth.
• Federal channel access: A distribution relationship with Red One Medical is positioned to open access to roughly 18 million federal healthcare beneficiaries, a potential long-term demand driver.
• Analyst support: Both covering firms hold buy ratings, and one raised its target in mid-2026, signaling a more constructive view of the commercial ramp.

What Could Prevent the Target From Being Reached

• Sequential revenue softness: Third-quarter revenue was guided to $2.3–$2.5 million, below the second quarter's $2.8 million, due to non-recurring international orders and seasonal slowdown.
• Persistent losses: The company remains unprofitable, with negative EPS and no clear near-term earnings floor to support a higher valuation.
• Capital needs and dilution: Milestone has used private placements and share-authorization increases to fund operations, which can pressure per-share value over time.
• Thin coverage and liquidity: A micro-cap with only two analysts and modest trading volume can be volatile, and a wide target range signals genuine disagreement about the business's trajectory.

Technical Levels and Market Structure

From a technical standpoint, the stock sits near $0.29, with a 52-week low around $0.22 acting as nearby support and the 52-week high near $0.58 serving as the first major resistance zone. The round-number $1.00 level is significant on two fronts: it is the conservative analyst target and a psychological barrier where investors often take profits. A sustained break above $0.58 would be a meaningful structural signal, while a loss of $0.22 would suggest renewed distribution pressure. The current chart reflects a name trading well below prior highs, with no established base yet in the $1.00–$1.50 range. One thing that stands out here is how thin the trading volume remains, which I’m watching closely for any signs of building interest.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a roughly 12-month research horizon, though the two firms covering MLSS have not published identical timeframes, and any horizon here is an assumption rather than a stated commitment. Investors should watch the third-quarter earnings report and its confirmation or revision of full-year guidance, any updates on federal healthcare reimbursement and Red One Medical adoption, and any new capital raises or dilution events. Changes to either of the two analyst targets, or the addition of new coverage, would also reshape the average target meaningfully.

Using AI Daily Buy/Sell Signals in Practice

In my own workflow, Tickeron's AI Daily Buy/Sell Signals have become a practical way to stay on top of evolving conditions across a wide range of names. The system scans thousands of stocks and ETFs in real time, surfacing Buy, Sell, or Hold signals based on technical behavior and market shifts. It serves as a useful complement when I want a systematic check alongside my own review of fundamentals and analyst views.

Final Assessment

The $1.25 figure is a calculated average of two analyst targets — $1.00 and $1.50 — not a guarantee, and with shares near $0.29, it implies a required move of roughly 330%, which is very large. The bull case rests on CompuFlo adoption, reaffirmed full-year guidance, and emerging federal distribution; the bear case rests on losses, a guided sequential revenue decline, thin coverage, and recurring financing needs. The unusually wide target range reflects genuine disagreement about how quickly Milestone can convert early traction into sustained, profitable growth. Reaching $1.25 would likely require not just execution but a fundamental re-rating of the stock, and investors should monitor earnings, guidance, adoption milestones, and any further capital activity before drawing conclusions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume